

Axel Benner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5859834/publications.pdf>

Version: 2024-02-01

50
papers

10,315
citations

201385

27
h-index

205818

48
g-index

51
all docs

51
docs citations

51
times ranked

12087
citing authors

#	ARTICLE	IF	CITATIONS
1	A consistent version of distance covariance for right-censored survival data and its application in hypothesis testing. <i>Biometrics</i> , 2022, 78, 867-879.	0.8	2
2	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.	3.3	42
3	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. <i>Leukemia</i> , 2022, 36, 885-888.	3.3	38
4	Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 352-361.	1.1	7
5	Midostaurin plus intensive chemotherapy for younger and older patients with AML and <i>FLT3</i> internal tandem duplications. <i>Blood Advances</i> , 2022, 6, 5345-5355.	2.5	24
6	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. <i>Leukemia</i> , 2021, 35, 809-822.	3.3	7
7	Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. <i>American Journal of Hematology</i> , 2021, 96, E253-E257.	2.0	13
8	Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up. <i>British Journal of Haematology</i> , 2021, 195, 230-243.	1.2	11
9	Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. <i>Cancers</i> , 2021, 13, 4856.	1.7	3
10	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 5395.	5.8	15
11	Marginal variable screening for survival endpoints. <i>Biometrical Journal</i> , 2020, 62, 610-626.	0.6	7
12	Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer. <i>Molecular Oncology</i> , 2020, 14, 8-21.	2.1	23
13	Adjusting Simon's optimal two-stage design for heterogeneous populations based on stratification or using historical controls. <i>Biometrical Journal</i> , 2020, 62, 311-329.	0.6	6
14	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. <i>Nature Protocols</i> , 2020, 15, 479-512.	5.5	89
15	Gemtuzumab Ozogamicin in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 623-632.	0.8	73
16	Polymorphisms in the Angiogenesis-Related Genes <i>EFNB2</i> , <i>MMP2</i> and <i>JAG1</i> Are Associated with Survival of Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5395.	1.8	12
17	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i> -mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020, 136, 3041-3050.	0.6	73
18	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. <i>Blood Advances</i> , 2020, 4, 6342-6352.	2.5	45

#	ARTICLE	IF	CITATIONS
19	Genotype-Based Gene Expression in Colon Tissueâ€”Prediction Accuracy and Relationship with the Prognosis of Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8150.	1.8	4
20	Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. <i>Blood</i> , 2020, 135, 1517-1530.	0.6	67
21	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	0.6	127
22	Genetic Variants in the Regulatory T cellâ€”Related Pathway and Colorectal Cancer Prognosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2719-2728.	1.1	1
23	Three brief pieces of statistical advice for medical peer reviewers. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13171.	1.7	0
24	Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1426.	1.7	27
25	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. <i>Haematologica</i> , 2019, 104, 1451-1459.	1.7	29
26	Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2019, 11, 822.	1.7	5
27	Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. <i>Blood Cancer Journal</i> , 2019, 9, 45.	2.8	7
28	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. <i>Blood</i> , 2019, 133, 840-851.	0.6	228
29	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	13.7	1,872
30	Prediction accuracy and variable selection for penalized causeâ€”specific hazards models. <i>Biometrical Journal</i> , 2018, 60, 288-306.	0.6	7
31	Tumor-derived exosomes modulate PD-L1 expression in monocytes. <i>Science Immunology</i> , 2017, 2, .	5.6	236
32	Relapsed/refractory acute myeloid leukemia: any progress?. <i>Current Opinion in Oncology</i> , 2017, 29, 467-473.	1.1	39
33	Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies. <i>Journal of Clinical Oncology</i> , 2017, 35, 3143-3152.	0.8	27
34	Drug-perturbation-based stratification of blood cancer. <i>Journal of Clinical Investigation</i> , 2017, 128, 427-445.	3.9	124
35	SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients. <i>International Journal of Cancer</i> , 2016, 138, 2993-3001.	2.3	34
36	Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. <i>Blood</i> , 2016, 128, 594-602.	0.6	67

#	ARTICLE	IF	CITATIONS
37	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. <i>Annals of Hematology</i> , 2016, 95, 1931-1942.	0.8	61
38	Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. <i>Journal of Clinical Oncology</i> , 2015, 33, 1371-1378.	0.8	185
39	Applying stability selection to consistently estimate sparse principal components in high-dimensional molecular data. <i>Bioinformatics</i> , 2015, 31, 2683-2690.	1.8	12
40	Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 9-17.	1.4	84
41	Differential impact of allelic ratio and insertion site in FLT3-ITD "positive AML with respect to allogeneic transplantation. <i>Blood</i> , 2014, 124, 3441-3449.	0.6	350
42	High-Dimensional Cox Models: The Choice of Penalty as Part of the Model Building Process. <i>Biometrical Journal</i> , 2010, 52, 50-69.	0.6	69
43	Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A. <i>Journal of Clinical Oncology</i> , 2010, 28, 4642-4648.	0.8	205
44	Computational Statistics Solutions for Molecular Biomedical Research: A Challenge and Chance for Both. , 2010, , 19-32.		0
45	Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. <i>Haematologica</i> , 2009, 94, 54-60.	1.7	195
46	Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2008, 358, 1909-1918.	13.9	1,514
47	T25 Repeat in the 3' Untranslated Region of the CASP2 Gene: A Sensitive and Specific Marker for Microsatellite Instability in Colorectal Cancer. <i>Cancer Research</i> , 2005, 65, 8072-8078.	0.4	125
48	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. <i>Blood</i> , 2002, 100, 4372-4380.	0.6	794
49	Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2000, 343, 1910-1916.	13.9	2,967
50	11q Deletions Identify a New Subset of B-Cell Chronic Lymphocytic Leukemia Characterized by Extensive Nodal Involvement and Inferior Prognosis. <i>Blood</i> , 1997, 89, 2516-2522.	0.6	363